TY - JOUR
T1 - Palliative meflep therapy in advanced pancreatic cancer
T2 - Excellent response in a patient with her-2/neu amplification
AU - Chao, Yee
AU - Liu, Jacqueline Ming
AU - YauLi, Anna Fen
AU - Perng, Ching Lin
AU - Tiu, Chue Mei
AU - King, Kuan Liang
AU - Chen, Li Tzong
AU - Lin, Wei Chun
AU - Lan, Chieh
AU - Whang-Peng, Jacqueline
PY - 2002/1/1
Y1 - 2002/1/1
N2 - Introduction Patients with pancreatic cancer often present initially in advanced disease with many compromising factors, and yet they may still be responsive to chemotherapy. Aims The response of 23 patients with advanced pancreatic cancer to continuous infusion therapy was investigated. Methodology From September 1995 to February 1998, 23 patients with advanced pancreatic cancer, many with compromising factors, were treated with a MEFLEP regimen: biweekly 24-hour infusions of etoposide, 5-fluorouracil, leucovorin, epirubicin, and cisplatin, all given through an infusion pump, plus megestrol acetate, 160 mg/d, taken daily. A total of 145 courses were given. Overall response rate was 21% (4/19) for assessable chemo-naive patients; median survival for all 23 patients was 6 months; 22% of patients were alive at 1 year; and a clinical response benefit was attained in 35%. Results Toxicity was manageable; grade 3 or 4 leukopenia occurred in 1 patient each, 1 patient had fever and grade 3 infection, and grade 3 and 4 hyperammonemic encephalopathy developed in 3 and 1 patients, respectively. All four of the latter patients recovered uneventfully within 2 days of initiation of therapy. Nine patients were evaluated by fluorescence in situ hybridization for the Her-2/ neu oncogene, but for only one patient did amplification of the gene occur. She attained complete remission with treatment and lived for 26.7 months after diagnosis. Conclusion Biweekly MEFLEP is an active and manageable regimen for patients with advanced pancreatic cancer with compromised clinical status.
AB - Introduction Patients with pancreatic cancer often present initially in advanced disease with many compromising factors, and yet they may still be responsive to chemotherapy. Aims The response of 23 patients with advanced pancreatic cancer to continuous infusion therapy was investigated. Methodology From September 1995 to February 1998, 23 patients with advanced pancreatic cancer, many with compromising factors, were treated with a MEFLEP regimen: biweekly 24-hour infusions of etoposide, 5-fluorouracil, leucovorin, epirubicin, and cisplatin, all given through an infusion pump, plus megestrol acetate, 160 mg/d, taken daily. A total of 145 courses were given. Overall response rate was 21% (4/19) for assessable chemo-naive patients; median survival for all 23 patients was 6 months; 22% of patients were alive at 1 year; and a clinical response benefit was attained in 35%. Results Toxicity was manageable; grade 3 or 4 leukopenia occurred in 1 patient each, 1 patient had fever and grade 3 infection, and grade 3 and 4 hyperammonemic encephalopathy developed in 3 and 1 patients, respectively. All four of the latter patients recovered uneventfully within 2 days of initiation of therapy. Nine patients were evaluated by fluorescence in situ hybridization for the Her-2/ neu oncogene, but for only one patient did amplification of the gene occur. She attained complete remission with treatment and lived for 26.7 months after diagnosis. Conclusion Biweekly MEFLEP is an active and manageable regimen for patients with advanced pancreatic cancer with compromised clinical status.
KW - Continuous infusion chemotherapy
KW - Megestrol acetate
KW - Pancreatic cancer
KW - Poor performance status
UR - http://www.scopus.com/inward/record.url?scp=18744393407&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=18744393407&partnerID=8YFLogxK
M3 - Article
C2 - 12131783
AN - SCOPUS:18744393407
SN - 0360-4039
VL - 25
JO - Nursing
JF - Nursing
IS - 1
ER -
